Downregulation of C1R promotes hepatocellular carcinoma development by activating HIF‐1α‐regulated glycolysis

Abstract

AbstractC1R has been identified to have a distinct function in cutaneous squamous cell carcinoma that goes beyond its role in the complement system. However, it is currently unknown whether C1R is involved in the progression of hepatocellular carcinoma (HCC). HCC tissues were used to examine C1R expression in relation to clinical and pathological factors. Malignant characteristics of HCC cells were assessed through in vitro and in vivo experiments. The mechanism underlying the role of C1R in HCC was explored through RNA‐seq, methylation‐specific PCR, immuno‐precipitation, and dual‐luciferase reporter assays. This study found that the expression of C1R decreased as the malignancy of HCC increased and was associated with poor prognosis. C1R promoter was highly methylated through DNMT1 and DNMT3a, resulting in a decrease in C1R expression. Downregulation of C1R expression resulted in heightened malignant characteristics of HCC cells through the activation of HIF‐1α‐mediated glycolysis. Additionally, decreased C1R expression was found to promote xenograft tumor formation. We found that C‐reactive protein (CRP) binds to C1R, and the free CRP activates the NF‐κB signaling pathway, which in turn boosts the expression of HIF‐1α. This increase in HIF‐1α leads to higher glycolysis levels, ultimately promoting aggressive behavior in HCC. Methylation of the C1R promoter region results in the downregulation of C1R expression in HCC. C1R inhibits aggressive behavior in HCC in vitro and in vivo by inhibiting HIF‐1α‐regulated glycolysis. These findings indicate that C1R acts as a tumor suppressor gene during HCC progression, opening up new possibilities for innovative therapeutic approaches.